Skip to main content

Table 4 Multivariate analysis of the inflammation-based cumulative prognostic score (ICPS) and IPI risk factors

From: An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era

Characteristic OS PFS
P-value HR (95% Cl) P-value HR (95% Cl)
Age(>60y) <0.001 2.493 (1.657–3.749) 0.250 1.228(0.865–1.745)
Ann Arbor stage(III,IV) 0.533 1.185(0.695–2.022) 0.295 1.254(0.821–1.914)
LDH(>245 U/L) 0.042 1.690(1.020–2.800) 0.018 1.642(1.087–2.479)
ECOG PS(≥2) 0.411 1.230(0.751–2.012) 0.022 1.579(1.069–2.330)
Extranodal sites(>1) 0.013 1.803(1.134–2.868) 0.187 1.305(0.879–1.937)
ICPS ≥ 2 0.001 2.476 (1.483–4.136) 0.019 1.611(1.080–2.404)
  1. Abbreviations: OS Overall survival, PFS Progression-free survival, HR Hazard Ratio, 95% Cl, 95% confidence limits, LDH Lactate dehydrogenase, ECOG PS Eastern Cooperative Oncology Group performance status, IPI International Prognostic Index, Hi High-intermediate, H High, ICPS Inflammation-based cumulative prognostic score
\